23andMe manufactured information in 2018 when it announced a $three hundred million, 4-calendar year deal to offer pharma giant GlaxoSmithKline access to its buyers’ genetic data. The primary drugs the two firms are engaged on collectively is an anti-cancer antibody, a spokesperson for 23andMe claimed in September 2020.Arrange DNA testing appoint